Home / Technology / Immune checkpoint inhibitor

Immune checkpoint inhibitor

Monoclonal antibodies targeting checkpoint inhibitors are hugely important cancer immunotherapeutics.

Numerous studies show that checkpoint inhibitors are effective for fighting cancer but only in a subset of patients (Postow et al, Frontiers in Oncology, 4, 385, 2015). Recent results on checkpoint inhibitor targets showed patient response rates between 10-37%.

Invectys is working on a very promising monoclonal antibody targeting a novel immune checkpoint.